Company / Operating Cash Flow
TELA Bio, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$40.9M
FY2025
5-year range
-$40.9M / -$24.5M
FY2021-FY2025
Trend
-0.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$24M in FY2022 to -$41M in FY2025.
Based on SEC 10-K filings.
-$41M in FY2025.
Declined from -$30M to -$41M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TELA Bio, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 0.3% year-over-year.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$40.9M | -0.3% |
| FY2024 | -$40.7M | -33.9% |
| FY2023 | -$30.4M | -24.4% |
| FY2022 | -$24.5M | +4.2% |
| FY2021 | -$25.5M | -28.1% |
| FY2020 | -$19.9M | -21.7% |
| FY2019 | -$16.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026